About: Natalizumab     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006. (en)
http://linked.open...y/drugbank/dosage
http://linked.open...generalReferences
  • # Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S: Natalizumab for active Crohn's disease. N Engl J Med. 2003 Jan 2;348(1):24-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12510039 # Patent Information "Link":http://www.patentstorm.us/patents/5840299/fulltext.html (en)
http://linked.open...gy/drugbank/group
  • approved (en)
  • investigational (en)
http://linked.open...drugbank/halfLife
  • 11 ± 4 days (en)
http://linked.open...ugbank/indication
  • For treatment of multiple sclerosis. (en)
sameAs
Title
  • Natalizumab (en)
adms:identifier
http://linked.open...mechanismOfAction
  • Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s). (en)
http://linked.open...drugbank/packager
http://linked.open.../drugbank/synonym
  • Anti-VLA4 (en)
  • Anti-alpha4 integrin (en)
http://linked.open...umeOfDistribution
  • * 5.7 ± 1.9 L [Multiple Sclerosis (MS) Patients] * 5.2 ± 2.8 L [Crohn's Disease (CD) Patients] (en)
http://linked.open.../drug/hasAHFSCode
foaf:page
http://linked.open...l/drug/hasATCCode
http://linked.open.../affectedOrganism
  • Humans and other mammals (en)
http://linked.open...casRegistryNumber
  • 189261-10-7 (en)
http://linked.open...drugbank/category
  • (en)
http://linked.open...rugbank/clearance
  • * 16 +/- 5 mL/hour [patients with MS who did not have PML receiving the repeat IV administration of a 300 mg dose] * 22 +/- 22 mL/hour [Patients with Crohn's Disease receiving the repeat IV administration of a 300 mg dose] (en)
http://linked.open...gbank/containedIn
http://linked.open...ank/Melting-Point
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 106 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software